SEC Form 3 · accession 0001179110-18-014234
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Glickman
Officer — Chief Commercial Officer
Period of report
Dec 20, 2018
Accepted (ET)
Dec 21, 2018 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $67.29 | holding | — | — | — | — | Apr 9, 2028 | Common Stock | 135,000 | — | D |
| Stock Option (right to buy)F3 | $52.38 | holding | — | — | — | — | Nov 28, 2028 | Common Stock | 33,000 | — | D |
Explanation of responses
- F1These shares were acquired pursuant to a restricted stock unit award under the 2017 Inducement Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. 25% of the restricted stock units vest on April 9, 2019 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter, subject to continued service.
- F225% of option vests on April 9, 2019 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.
- F325% of option vests on November 28, 2019 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.